

Publications Generated as Result of John C Martin Foundation Support of the Polaris Observatory

Razavi-Shearer D. **The economic argument for hepatitis B treatment simplification and expansion.** *J Viral Hepat.* 2024;00:1-4. <https://doi.org/10.1111/jvh.13920>

Polaris Observatory Collaborators. **Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories.** *J Hepatol.* 2024;80(2):232-242. <https://doi.org/10.1016/j.jhep.2023.10.043>

Cui F, Blach S, Manzeno Mingiedi C, et al. **Global reporting of progress towards elimination of hepatitis B and hepatitis C.** *Lancet Gastroenterol Hepatol.* 2023;8(4):332-342. [https://doi.org/10.1016/S2468-1253\(22\)00386-7](https://doi.org/10.1016/S2468-1253(22)00386-7)

Ezzat S, Gamkrelidze I, Osman A, et al. **Impacts of the Egyptian national screening and treatment programme for viral hepatitis C: A cost-effectiveness model.** *Liver Int.* 2023;43(7):1417-1426. <https://doi.org/10.1111/liv.15584>

Matthews PC, Ocamo P, Wang S, et al. **Enhancing interventions for prevention of mother-to-child- transmission of hepatitis B virus.** *JHEP Rep.* 2023;5(8):100777. <https://doi.org/10.1016/j.jhepr.2023.100777>

Mooneyhan E, Qureshi H, Mahmood H, et al. **Hepatitis C prevalence and elimination planning in Pakistan, a bottom-up approach accounting for provincial variation.** *J Viral Hepat.* 2023;30(4):345-354. <https://doi.org/10.1111/jvh.13802>

Musabaev E, Estes C, Sadirova S, et al. **Viral hepatitis elimination challenges in low- and middle-income countries- Uzbekistan Hepatitis Elimination Program (UHEP).** *Liver Int.* 2023;43(4):773-784. <https://doi.org/10.1111/liv.15514>

Polaris Observatory Collaborators. **Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study.** *Lancet Gastroenterol Hepatol.* 2023;8(10):879-907. [https://doi.org/10.1016/S2468-1253\(23\)00197-8](https://doi.org/10.1016/S2468-1253(23)00197-8)

Razavi-Shearer D, Gamkrelidze I, Pan CQ, et al. **The impact of immigration on hepatitis B burden in the United States: a modelling study.** *Lancet Reg Health Am.* 2023 May 27;22:100516. <https://doi.org/10.1016/j.lana.2023.100516>

CDA Foundation; Coalition for Global Hepatitis Elimination, Hepatitis Australia; Hepatitis Fund; Hepatitis B Foundation, Médecins Sans Frontières Access Campaign; PATH, TREAT Asia/amfAR, The Foundation for AIDS Research, Union for International Cancer Control; World Hepatitis Alliance. **An open letter to Gavi: hepatitis B birth dose vaccine can't wait.** *Lancet Gastroenterol Hepatol.* 2023;8(2):115-116. [https://doi.org/10.1016/S2468-1253\(22\)00422-8](https://doi.org/10.1016/S2468-1253(22)00422-8)

Le LV, Blach S, Rewari B, et al. **Progress towards achieving viral hepatitis B and C elimination in the Asia and Pacific region: Results from modelling and global reporting.** *Liver Int.* 2022;42(9):1930-1934. <https://doi.org/10.1111/liv.15131>

Polaris Observatory HCV Collaborators. **Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study.** *Lancet Gastroenterol Hepatol.* 2022;7(5):396-415. [https://doi.org/10.1016/S2468-1253\(21\)00472-6](https://doi.org/10.1016/S2468-1253(21)00472-6)

Razavi H. **Polaris Observatory-supporting informed decision-making at the national, regional, and global levels to eliminate viral hepatitis.** *Antivir Ther.* 2022;27(2):13596535221083179. <https://doi.org/10.1177/13596535221083179>

Blach S, Kondili LA, Aghemo A, et al. **Impact of COVID-19 on global HCV elimination efforts.** *J Hepatol.* 2021;74(1):31-6. <https://doi.org/10.1016/j.jhep.2020.07.042>

Dugan E, Blach S, Biondi M, et al. **Global prevalence of hepatitis C virus in women of childbearing age in 2019: a modelling study.** *Lancet Gastroenterol Hepatol.* 2021;6(3):169-84. [https://doi.org/10.1016/S2468-1253\(20\)30359-9](https://doi.org/10.1016/S2468-1253(20)30359-9)

Li X, Mukandavire C, Cucunubá ZM, et al. **Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study.** *Lancet*. 2021;397(10275):398-408. [https://doi.org/10.1016/S0140-6736\(20\)32657-X](https://doi.org/10.1016/S0140-6736(20)32657-X)

Polaris Observatory Collaborators. **The case for simplifying and using absolute targets for viral hepatitis elimination goals.** *J Viral Hepat*. 2021;28(1):12-19. <https://doi.org/10.1111/jvh.13412>

Toor J, Echeverria-Londono S, Li X, et al. **Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world.** *Elife*. 2021;10:e67653. <https://doi.org/10.7554/eLife.67635>

de Villiers MJ, Gamkrelidze I, Hallett TB, et al. **Modelling hepatitis B virus infection and impact of timely birth dose vaccine: A comparison of two simulation models.** *PLoS One*. 2020;15(8):e0237525. <https://doi.org/10.1371/journal.pone.0237525>

Dunn R, Musabaev E, Razavi H, et al. **Progress Toward Hepatitis B and Hepatitis C Elimination Using a Catalytic Funding Model - Tashkent, Uzbekistan.** *MMWR Morb Mortal Wkly Rep*. 2020;69(34):1161-1165. <https://doi.org/10.15585/mmwr.mm6934a3>

Palayew A, Razavi H, Hutchinson SJ, et al. **Do the most heavily burdened countries have the right policies to eliminate viral hepatitis B and C?** *Lancet Gastroenterol Hepatol*. 2020;5(10):948-953. [https://doi.org/10.1016/S2468-1253\(20\)30011-X](https://doi.org/10.1016/S2468-1253(20)30011-X)

Razavi H. **Global Epidemiology of Viral Hepatitis.** *Gastroenterol Clin North Am*. 2020;49(2):179-89. <https://doi.org/10.1016/j.gtc.2020.01.001>

Schmelzer J, Dugan E, Blach S, et al. **Global prevalence of hepatitis C virus in children in 2018: a modelling study.** *Lancet Gastroenterology & Hepatology*. 2020;5(4):374-392. [https://doi.org/10.1016/S2468-1253\(19\)30385-1](https://doi.org/10.1016/S2468-1253(19)30385-1)

Cooke GS, Andrieux-Meyer I, Applegate TL, et al. **Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission.** *Lancet Gastroenterol Hepatol*. 2019;4(2):135-184. [https://doi.org/10.1016/S2468-1253\(18\)30270-X](https://doi.org/10.1016/S2468-1253(18)30270-X)

Fraňková S, Urbánek P, Husa P, et al. **Chronic hepatitis C in the Czech Republic: Forecasting the disease burden.** *Cent Eur J Public Health*. 2019;27(2):93-98. <https://doi.org/10.21101/cejph.a5350>

Gountas I, Sypsa V, Papatheodoridis G, et al. **Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.** *World J Gastroenterol*. 2019 Mar 21;25(11):1327-1340. <http://doi.org/10.3748/wjg.v25.i11.1327>

Grebely J, Larney S, Peacock A, et al. **Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs.** *Addiction*. 2019;114(1):150-166. <https://doi.org/10.1111/add.14393>

Lee KK, Stelzle D, Bing R, et al. **Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study.** *Lancet Gastroenterol Hepatol*. 2019;4(10):794-804. [https://doi.org/10.1016/S2468-1253\(19\)30227-4](https://doi.org/10.1016/S2468-1253(19)30227-4)

Safreed-Harmon K, Blach S, Aleman S, et al. **The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination.** *Clin Infect Dis*. 2019;69(12):2218-2227. <https://doi.org/10.1093/cid/ciz714>

Gountas I, Sypsa V, Blach S, et al. **HCV elimination among people who inject drugs. Modelling pre- and post-WHO elimination era.** *PLoS One*. 2018;13(8):e0202109. <https://doi.org/10.1371/journal.pone.0202109>

Hecht R, Hiebert L, Spearman WC, et al. **The investment case for hepatitis B and C in South Africa: adaptation and innovation in policy analysis for disease program scale-up.** *Health Policy Plan.* 2018;33(4):528-538. <https://doi.org/10.1093/heapol/czy018>

Kondili LA, Robbins S, Blach S, et al. **Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?.** *Liver Int.* 2018;38(12):2190-2198. <https://doi.org/doi:10.1111/liv.13901>

Lazarus JV, Block T, Brechot C, et al. **The hepatitis B epidemic and the urgent need for cure preparedness.** *Nature Reviews Gastroenterology & Hepatology.* 2018;15:517-518. <https://doi.org/10.1038/s41575-018-0041-6>

The Polaris Observatory Collaborators. **Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study.** *Lancet Gastroenterol Hepatol.* 2018;3(6):383-403. [https://doi.org/10.1016/S2468-1253\(18\)30056-6](https://doi.org/10.1016/S2468-1253(18)30056-6)

The Polaris Observatory HCV Collaborators. **Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.** *Lancet Gastroenterology & Hepatology.* 2017;2(3):161-76. [https://doi.org/10.1016/S2468-1253\(16\)30181-9](https://doi.org/10.1016/S2468-1253(16)30181-9)

Bruggmann P, Blach S, Deltenre P, et al. **Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030.** *Swiss Med Wkly.* 2017;147:w14543. <https://doi.org/10.4414/smw.2017.14543>

Gountas I, Sympa V, Papatheodoridis G, et al. **Is elimination of HCV possible in a country with low diagnostic rate and moderate HCV prevalence?: The case of Greece.** *J Gastroenterol Hepatol.* 2017;32(2):466-472. <https://doi.org/10.1111/jgh.13485>

Kondili LA, Romano F, Rolli FR, et al. **Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort.** *Hepatology.* 2017;66(6):1814-25. <https://doi.org/10.1002/hep.29399>

Manns MP, Buti M, Gane E, et al. **Hepatitis C virus infection.** *Nat Rev Dis Primers.* 2017;3:17006. <https://doi.org/10.1038/nrdp.2017.6>

Örmeci N, Malhan S, Balık İ, et al. **Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey.** *Hepatology International.* 2017;11(6):509-16. <https://doi.org/10.1007/s12072-017-9820-3>

Aljumah, Abdulrahman A, Abaalkhail F, Al-Ashgar H, et al. **Epidemiology, disease burden, and treatment strategies of chronic hepatitis C virus infections in Saudi Arabia in the new treatment paradigm shift.** *Saudi Journal of Gastroenterology.* 2016;22(4):269-81. <https://doi.org/10.4103/1319-3767.187609>

Hajarizadeh B, Razavi-Shearer D, Merat S, et al. **Liver Disease Burden of Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease Burden.** *Hepat Mon.* 2016;16(7):e37234. <http://doi.org/10.5812/hepatmon.37234>

Ridruejo E, Bessone F, Daruich JR, et al. **Hepatitis C virus infection in Argentina: Burden of chronic disease.** *World J Hepatol.* 2016;8(15):649-58. <http://doi.org/10.4254/wjh.v8.i15.649>

Robaey G, Bielen R, Azar DG, et al. **Global genotype distribution of hepatitis C viral infection among people who inject drugs.** *J Hepatol.* 2016;65(6):1094-1103. <http://doi.org/10.1016/j.jhep.2016.07.042>